In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
The Gastrointestinal Pathogen Panel is the first of a number of planned infectious disease syndromic panels on the firm's PCR-based system.
The acquisition merges OvaGene's liquid biopsy technology and molecular diagnostics with Etta's point-of-care system.
The assay was demonstrated to be as effective as microscopy and a rapid immunoassay at detecting Plasmodium falciparum in a sample of febrile patients in Nigeria.
Building on a recent point-counterpoint in the Journal of Clinical Microbiology, lab directors discuss pros and cons of large MDx panels for infectious disease testing.
Originally published May 7.
Strong sales of its clinical systems and consumables pushed the firm's top line up 35 percent, while Cepheid turned in its third consecutive quarter of GAAP profitability.
The acquisition is expected to help build Myriad's companion diagnostics franchise.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.